Pneumonia Therapeutics Market Poised for Strong Expansion at 7.5% CAGR to 2031, Fueled by North America's Largest Nearly 40% Share | DataM Intelligence

The Global Pneumonia Therapeutics Market is expected to grow at a steady CAGR of 7.5% during the forecast period 2024-2031.

Market growth is propelled by the rising global incidence of pneumonia, increasing demand for advanced antibiotic therapies, and expanding R&D investments in novel drug formulations. Additionally, growing awareness of early diagnosis and improved healthcare access in emerging markets are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/pneumonia-therapeutics-market?ram

United States: Key Industry Developments
✅ July 2025: Innoviva Specialty Therapeutics commercially launched ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic approved for treating community-acquired bacterial pneumonia in adults and pediatric patients aged three months to under 18 years, addressing drug-resistant pathogens in hospital and outpatient settings.​

Asia Pacific / Japan: Key Industry Developments
✅ May 2024: Zai Lab and Innoviva Specialty Therapeutics secured NMPA approval for XACDURO (sulbactam-durlobactam) in China to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex, enhancing access to novel therapies amid rising antimicrobial resistance.

Key Merges and Acquisitions(2025):
✅ Johnson & Johnson's Acquisition of Intra-Cellular Therapies (Indirect Impact): In 2025, Johnson & Johnson announced the acquisition of Intra-Cellular Therapies for $14.6 billion. This deal reflects a broader trend of major pharmaceutical companies acquiring innovative biotechs to bolster their pipelines, a dynamic also seen in the push for novel pneumonia treatments.

✅ Google's Acquisition of Wiz (Indirect Impact): In March 2025, Google acquired the cybersecurity firm Wiz for $32 billion, one of the year's largest tech deals. This highlights the massive push for integrated data management and AI capabilities across industries, which is also relevant to healthcare data analytics in the pneumonia market.

✅ Tata Motors acquires Iveco (Indirect Impact): Tata Motors' acquisition of Iveco for $4.45 billion in 2025 showcases growing global expansion strategies for large corporations. Similarly, major pharmaceutical players in the pneumonia therapeutics market are expanding their reach into emerging markets like the Asia-Pacific region to capitalize on high growth potential.

Market Segmentation Analysis:
-By Type: Community-Acquired Pneumonia Leads
Community-acquired pneumonia (CAP) holds 51.4% market share in 2024, driven by high incidence from diverse pathogens, age-related risks, smoking, and environmental factors leading to elevated mortality.​
Hospital-acquired pneumonia (HAP), healthcare-associated pneumonia, ventilator-associated pneumonia (VAP), and aspiration pneumonia follow with smaller shares, often linked to nosocomial infections and critical care needs.​

-By Treatment: Antibacterial Drugs Dominate
Antibacterial drugs lead due to their classification into quinolones, macrolides, and others, targeting prevalent bacterial causes effectively.​
Prevention vaccines focus on immunization, while antifungal and antiviral drugs address specific fungal or viral pathogens, contributing lesser shares amid rising resistance challenges.​

-By Route of Administration: Oral Prevails
Oral administration commands 55.5% market share in 2024, favored for convenience, high patient compliance, and ease of use in outpatient settings.​
Parenteral routes suit severe cases requiring rapid action, with others like inhalation playing niche roles in targeted delivery.​

-By Distribution Channel: Hospital Pharmacy Leads
Hospital pharmacies hold the top share at around 53.1% via hospitals and clinics, offering immediate access to diagnostics, complex regimens, and severe case management like HAP and VAP.​
Retail and online pharmacies support milder cases and homecare, growing with outpatient shifts but trailing hospital dominance.​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=pneumonia-therapeutics-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising Global Incidence of Pneumonia: The market expands due to high prevalence among vulnerable groups like children under five and the elderly, with pneumonia causing significant annual deaths worldwide.​

-Escalating Antibiotic Resistance: Growing resistance to common pathogens like Streptococcus pneumoniae drives demand for innovative antibiotics, antivirals, and new therapies.​

-Advancements in Diagnostics and R&D: Progress in molecular diagnostics, point-of-care testing, and pharmaceutical research enables faster pathogen identification and tailored treatments, boosting therapeutic adoption.​

-Increasing Awareness and Early Treatment: Heightened public and healthcare focus on early diagnosis and prevention, supported by government initiatives, increases demand for effective pneumonia drugs.​

-Prevalence of Community-Acquired Pneumonia (CAP): Surge in CAP cases, particularly in regions with large patient populations, fuels market growth alongside new product launches and clinical trials.​

Regional Insights:
-North America holds the largest share of the Pneumonia Therapeutics Market, accounting for nearly 40% of global demand, driven by advanced healthcare infrastructure, robust research capabilities, and strong hospital partnerships.​

-Europe follows with a steady market share, supported by favorable regulatory frameworks and widespread clinical adoption of pneumonia treatments across key countries.​

-Asia Pacific captures over 25% of the market and exhibits the fastest growth, fueled by rising pneumonia prevalence, increasing healthcare investments, and rapid expansion in countries like China and India.​

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pneumonia-therapeutics-market?ram

Key Players:
Pfizer Inc. | Dr. Reddy's Laboratories | LGM Pharma LLC | Teva Pharmaceuticals Ltd. | AdvaCare Pharma | Baxter International Inc. | Innoviva Specialty Therapeutics Inc. | F. Hoffmann-La Roche Ltd. | Sanofi S.A | Lupin Limited.

Key Highlights (Top 5 Key Players) for Pneumonia Therapeutics Market:
-Pfizer Inc. leads with approximately 11.4% market share in 2024, driven by its Prevnar vaccine series generating USD 6.4 billion in global revenues, representing a key portion of pneumonia prevention sales.​

-GlaxoSmithKline (GSK) holds a significant position through broad-spectrum antibiotics and respiratory vaccines, contributing to the top players' collective 60% market dominance alongside Pfizer and others.​

-F. Hoffmann-La Roche Ltd competes via specialized therapies and biologics in the pneumonia landscape, supported by ongoing R&D investments amid a market valued at USD 3.3 billion in 2024.​

-Sanofi S.A. advances through generics, vaccines, and global distribution networks, gaining traction in underserved markets as part of emerging players in this USD 3.6 billion projected 2025 sector.​

-Lupin Limited strengthens its role with affordable anti-infectives and generics, bolstering the competitive field where leading firms focus on innovation and regulatory approvals.​

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.